Key result
Subcutaneous maropitant induces slight QTc prolongation and reduced P wave amplitude without clinical relevance.
Why the study?
To evaluate electrocardiographic changes, especially involving the QT interval, following maropitant administration in healthy dogs and to compare methods of QT interval correction.
Does maropitant alter ECG parameters, particularly the QT interval, in healthy dogs?
Does maropitant alter ECG parameters, particularly the QT interval, in healthy dogs?
Maropitant at standard antiemetic doses induces slight QTc prolongation and reduced P wave amplitude in healthy dogs, but these changes are unlikely to be clinically relevant or promote tachyarrhythmias.
Answers are grounded in this paper and cite their sources.
Reassures against QT concerns with maropitant in healthy dogs; leaves open effects in clinical patients with comorbidities.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2025) studied Healthy dogs (n=20). Maropitant vs. Baseline was evaluated on ECG changes, particularly affecting the QT interval. Maropitant administered subcutaneously induced a slight prolongation of the QTc and a reduction in P wave amplitude that are unlikely to promote tachyarrhythmias or become clinically relevant.
Synapse has enriched 10 related papers. Consider them for comparative context: